Medtronic, the global leader in medical technology, today announced new randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug coated balloon (DCB) compared to percutaneous transluminal angioplasty (PTA) through 36 months, with no difference in mortality. The data was presented today as a podium first at the 2022 Charing Cross Symposium in London.